Chemotherapy as a regulator of extracellular matrix-cell communication: Implications in therapy resistance

Semin Cancer Biol. 2022 Nov;86(Pt 3):224-236. doi: 10.1016/j.semcancer.2022.03.012. Epub 2022 Mar 21.

Abstract

The development of most solid cancers, including pancreatic, breast, lung, liver, and ovarian cancer, involves a desmoplastic reaction: a process of major remodeling of the extracellular matrix (ECM) affecting the ECM composition, mechanics, and microarchitecture. These properties of the ECM influence key cancer cell functions, including treatment resistance. Furthermore, emerging data show that various chemotherapeutic treatments lead to alterations in ECM features and ECM-cell communication. Here, we summarize the current knowledge around the effects of chemotherapy on both the ECM remodeling and ECM-cell signaling and discuss the implications of these alterations on distinct mechanisms of chemoresistance. Additionally, we provide an overview of current therapeutic strategies and ongoing clinical trials utilizing anti-cancer drugs to target the ECM-cell communication and explore the future challenges of these strategies.

Keywords: Cancer; Chemoresistance; Chemotherapy; ECM; Plasticity.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Cell Communication
  • Extracellular Matrix
  • Humans
  • Neoplasms* / drug therapy

Substances

  • Antineoplastic Agents